I'm LongbridgeAI, I can summarize articles.SBC Medical Group Holdings reported weaker Q1 2026 results, with revenue of $43 million (down 9% YoY) and net income of $11 million (down 47%). Despite these declines, the company noted growth in franchise locations and customer base. Management plans to drive growth through a multi-brand strategy and expansion into new markets. The stock has a Buy rating with a $9.00 price target, while Spark's AI Analyst rates it as Neutral due to profitability and balance-sheet strength, offset by revenue contraction. SBC Medical focuses on advanced aesthetic healthcare and is expanding globally.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SBC Medical Group Holdings ( (SBC) ) has provided an update.
On May 14, 2026, SBC Medical Group Holdings reported first-quarter 2026 results showing $43 million in revenue, down 9% year over year, and net income of $11 million, a 47% decline with margin compressed to 26%. EBITDA fell 26% to $18 million with a 43% margin, while return on equity dropped to 18%, reflecting the financial impact of an April 2025 structural reform that revised the franchise fee model.
Despite weaker earnings, operating metrics pointed to continued business expansion, with franchise locations rising to 284, customers in the past 12 months increasing 10% to 6.76 million and a 72% repeat visit rate. Management highlighted that core operations remained solid excluding the fee-structure change and underscored plans to drive growth via a multi-brand strategy in aesthetic dermatology, expansion of non-aesthetic and overseas businesses, and new initiatives in the longevity and AI-enabled healthcare markets.
The company also posted a first-quarter 2026 investor presentation on its website and reiterated that its online channels are an important distribution point for potentially material investor information. SBC Medical scheduled a conference call for May 14, 2026 to discuss the quarterly results with analysts and investors, with accompanying materials and an archived webcast available through its investor relations site.
The most recent analyst rating on (SBC) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on SBC Medical Group Holdings stock, see the SBC Stock Forecast page.
Spark’s Take on SBC Stock
According to Spark, TipRanks’ AI Analyst, SBC is a Neutral.
The score is driven primarily by solid profitability and balance-sheet strength, partially offset by 2025 revenue contraction and less consistent cash conversion. Valuation is attractive on a low P/E, while technicals remain weak-to-neutral with price below key longer-term averages. Corporate actions are broadly positive (U.S. expansion and buyback), tempered by potential dilution risk from the shelf registration.
To see Spark’s full report on SBC stock, click here.
More about SBC Medical Group Holdings
SBC Medical Group Holdings is a medical services organization that provides management support across advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment and ophthalmology. The company operates a portfolio of clinic brands and is expanding globally, with a particular focus on the United States and Asia through direct operations and medical tourism initiatives.
Listed on Nasdaq since September 2024 and included in the Russell 3000 Index since June 2025, SBC Medical aims to build a sustainable healthcare platform centered on medical innovation. It emphasizes safe, high-quality services and seeks to strengthen its international reputation and brand through a multi-brand strategy and expansion in non-aesthetic medical segments.
Average Trading Volume: 86,848
Technical Sentiment Signal: Sell
Current Market Cap: $339.5M
Find detailed analytics on SBC stock on TipRanks’ Stock Analysis page.